This comprehensive review explores that subjoining of alpha-tocopherol (vitamin E) have improved effect on cardiovascular biomarkers in the human subjects, focusing on its potential role in addressing cardiovascular diseases (CVDs), which are major global health challenges exacerbated by risk factors such as dyslipidaemia and hypertension. Systematic analysis of various randomized controlled trials, evaluates alpha-tocopherol's effects on LDL cholesterol, HDL cholesterol, systolic blood pressure, triglycerides, total cholesterol levels etc. The synthesis of current literature consistently indicates that alpha-tocopherol treatment leads to significant reductions in systolic blood pressure compared to control groups. Furthermore, substantial evidence supports alpha-tocopherol's ability to increase HDL-cholesterol levels and decrease LDL-cholesterol concentrations, suggesting beneficial impacts on lipid profiles. The review also discusses alphatocopherol's influence on additional cardiovascular biomarkers such as Troponin I, B-type Natriuretic Peptide (BNP), Nterminal pro-BNP, Troponin T, C-reactive Protein (CRP), Lipoproteins, Creatine Kinase-MB (CK-MB), Myoglobin, and Fibrinogen, highlighting its potential broader effects on cardiovascular health indicators. Overall, this review underscores alpha-tocopherol's potential as an adjunctive therapy for managing cardiovascular risk factors, particularly hypertension and dyslipidemia. The findings suggest that alpha-tocopherol supplementation may induce favourable changes in cardiovascular biomarkers, offering insights into its therapeutic potential and calling for further investigation in clinical settings.
Read full abstract